Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
2.

Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.

Di Malta C, Siciliano D, Calcagni A, Monfregola J, Punzi S, Pastore N, Eastes AN, Davis O, De Cegli R, Zampelli A, Di Giovannantonio LG, Nusco E, Platt N, Guida A, Ogmundsdottir MH, Lanfrancone L, Perera RM, Zoncu R, Pelicci PG, Settembre C, Ballabio A.

Science. 2017 Jun 16;356(6343):1188-1192. doi: 10.1126/science.aag2553.

3.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

PMID:
28104906
4.

Dual modulation of MCL-1 and mTOR determines the response to sunitinib.

Elgendy M, Abdel-Aziz AK, Renne SL, Bornaghi V, Procopio G, Colecchia M, Kanesvaran R, Toh CK, Bossi D, Pallavicini I, Perez-Gracia JL, Lozano MD, Giandomenico V, Mercurio C, Lanfrancone L, Fazio N, Nole F, Teh BT, Renne G, Minucci S.

J Clin Invest. 2017 Jan 3;127(1):153-168. doi: 10.1172/JCI84386. Epub 2016 Nov 28.

5.

RNAi screens identify CHD4 as an essential gene in breast cancer growth.

D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L.

Oncotarget. 2016 Dec 6;7(49):80901-80915. doi: 10.18632/oncotarget.12646.

6.

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF.

Cell Rep. 2016 Jun 28;16(1):133-147. doi: 10.1016/j.celrep.2016.05.063. Epub 2016 Jun 16.

7.

In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni G, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci P, Lanfrancone L.

Cancer Discov. 2016 Jun;6(6):650-63. doi: 10.1158/2159-8290.CD-15-1200. Epub 2016 May 13.

8.

Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.

Elgendy M, Ciro M, Abdel-Aziz AK, Belmonte G, Dal Zuffo R, Mercurio C, Miracco C, Lanfrancone L, Foiani M, Minucci S.

Nat Commun. 2014 Dec 4;5:5637. doi: 10.1038/ncomms6637.

9.

Investigating the metastatic niche in melanoma: a new therapeutic opportunity?

Aladowicz E, Lanfrancone L.

Future Oncol. 2014 Apr;10(5):699-701. doi: 10.2217/fon.14.26. No abstract available.

10.

Molecular networks in melanoma invasion and metastasis.

Aladowicz E, Ferro L, Vitali GC, Venditti E, Fornasari L, Lanfrancone L.

Future Oncol. 2013 May;9(5):713-26. doi: 10.2217/fon.13.9. Review.

PMID:
23647299
11.

Cellular heterogeneity during embryonic stem cell differentiation to epiblast stem cells is revealed by the ShcD/RaLP adaptor protein.

Turco MY, Furia L, Dietze A, Fernandez Diaz L, Ronzoni S, Sciullo A, Simeone A, Constam D, Faretta M, Lanfrancone L.

Stem Cells. 2012 Nov;30(11):2423-36. doi: 10.1002/stem.1217.

12.

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, Calogero R, Moll J, Isacchi A.

Gene. 2012 Feb 25;494(2):202-8. doi: 10.1016/j.gene.2011.08.014. Epub 2011 Sep 2.

PMID:
21914463
13.

Pirin inhibits cellular senescence in melanocytic cells.

Licciulli S, Luise C, Scafetta G, Capra M, Giardina G, Nuciforo P, Bosari S, Viale G, Mazzarol G, Tonelli C, Lanfrancone L, Alcalay M.

Am J Pathol. 2011 May;178(5):2397-406. doi: 10.1016/j.ajpath.2011.01.019.

14.

Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches.

Licciulli S, Luise C, Zanardi A, Giorgetti L, Viale G, Lanfrancone L, Carbone R, Alcalay M.

BMC Cell Biol. 2010 Jan 20;11:5. doi: 10.1186/1471-2121-11-5.

15.

Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells.

Santoriello C, Deflorian G, Pezzimenti F, Kawakami K, Lanfrancone L, d'Adda di Fagagna F, Mione M.

Dis Model Mech. 2009 Jan-Feb;2(1-2):56-67. doi: 10.1242/dmm.001016. Epub 2008 Dec 22.

16.

Melanoma: targeting signaling pathways and RaLP.

Pasini L, Turco MY, Luzi L, Aladowicz E, Fagiani E, Lanfrancone L.

Expert Opin Ther Targets. 2009 Jan;13(1):93-104. doi: 10.1517/14728220802607363 .

PMID:
19063709
17.

Tbx3 represses E-cadherin expression and enhances melanoma invasiveness.

Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR.

Cancer Res. 2008 Oct 1;68(19):7872-81. doi: 10.1158/0008-5472.CAN-08-0301.

18.

The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity.

Finetti F, Pellegrini M, Ulivieri C, Savino MT, Paccagnini E, Ginanneschi C, Lanfrancone L, Pelicci PG, Baldari CT.

Blood. 2008 May 15;111(10):5017-27. doi: 10.1182/blood-2007-12-130856. Epub 2008 Mar 11.

19.

p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells.

Patrussi L, Ulivieri C, Lucherini OM, Paccani SR, Gamberucci A, Lanfrancone L, Pelicci PG, Baldari CT.

Blood. 2007 Sep 15;110(6):1730-8. Epub 2007 May 30.

20.

RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.

Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, Germano G, Bono M, Capillo M, Pelicci P, Lanfrancone L.

Cancer Res. 2007 Apr 1;67(7):3064-73.

21.

Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage.

Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu P, Quaini F, Padura IM, Lanfrancone L, Pelicci P, Emanueli C.

Hypertension. 2005 Aug;46(2):433-40. Epub 2005 Jul 5.

22.

Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival.

Patrussi L, Savino MT, Pellegrini M, Paccani SR, Migliaccio E, Plyte S, Lanfrancone L, Pelicci PG, Baldari CT.

Oncogene. 2005 Mar 24;24(13):2218-28.

PMID:
15688026
23.

The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential.

Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, Pelicci PG.

J Biol Chem. 2004 Jun 11;279(24):25689-95. Epub 2004 Apr 12.

24.

p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells.

Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Ulivieri C, Ventura A, Carraro F, Naldini A, Lanfrancone L, Pelicci P, Baldari CT.

Mol Cell Biol. 2004 Feb;24(4):1747-57.

25.

Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells.

Audero E, Cascone I, Maniero F, Napione L, Arese M, Lanfrancone L, Bussolino F.

J Biol Chem. 2004 Mar 26;279(13):13224-33. Epub 2003 Dec 9.

26.

A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis.

Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, Pelicci PG.

Oncogene. 2002 May 30;21(24):3872-8.

27.

Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling.

Zanetti A, Lampugnani MG, Balconi G, Breviario F, Corada M, Lanfrancone L, Dejana E.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):617-22.

28.

The adaptor protein shc is involved in the negative regulation of NK cell-mediated cytotoxicity.

Galandrini R, Tassi I, Morrone S, Lanfrancone L, Pelicci P, Piccoli M, Frati L, Santoni A.

Eur J Immunol. 2001 Jul;31(7):2016-25.

29.

Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.

Gerli R, Gresele P, Bistoni O, Paolucci C, Lanfrancone L, Fiorucci S, Muscat C, Costantini V.

J Immunol. 2001 Jan 15;166(2):832-40.

30.

Human endothelial cells expressing polyoma middle T induce tumors.

Primo L, Roca C, Ferrandi C, Lanfrancone L, Bussolino F.

Oncogene. 2000 Jul 27;19(32):3632-41.

31.

Constitutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the Shc adaptor to membrane rafts.

Plyte S, Majolini MB, Pacini S, Scarpini F, Bianchini C, Lanfrancone L, Pelicci P, Baldari CT.

Oncogene. 2000 Mar 16;19(12):1529-37.

32.

A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.

Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pelicci PG, Falini B.

Cancer Res. 2000 Feb 15;60(4):793-8.

33.

The p66shc adaptor protein controls oxidative stress response and life span in mammals.

Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG.

Nature. 1999 Nov 18;402(6759):309-13.

PMID:
10580504
34.

Retroviral gene transfer, rapid selection, and maintenance of the immature phenotype in mouse dendritic cells.

Gasperi C, Rescigno M, Granucci F, Citterio S, Matyszak MK, Sciurpi MT, Lanfrancone L, Ricciardi-Gastagnoli P.

J Leukoc Biol. 1999 Aug;66(2):263-7.

35.

Bombesin-induced pancreatic regeneration in pigs is mediated by p46Shc/p52Shc and p42/p44 mitogen-activated protein kinase upregulation.

Fiorucci S, Bufalari A, Distrutti E, Bufalari A, Lanfrancone L, Servoli A, Sarpi L, Federici B, Bartoli A, Morelli A, Moggi L.

Scand J Gastroenterol. 1998 Dec;33(12):1310-20.

PMID:
9930396
36.

c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.

Brizzi MF, Rosso A, Dentelli P, Ferrero D, Lanfrancone L, Pegoraro L.

Exp Hematol. 1998 Dec;26(13):1229-39.

PMID:
9845379
37.

Tyrosine 474 of ZAP-70 is required for association with the Shc adaptor and for T-cell antigen receptor-dependent gene activation.

Pacini S, Ulivieri C, Di Somma MM, Isacchi A, Lanfrancone L, Pelicci PG, Telford JL, Baldari CT.

J Biol Chem. 1998 Aug 7;273(32):20487-93.

38.

High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein.

Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, Pelicci PG.

Cancer Res. 1998 Jan 1;58(1):14-9.

39.

Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides.

Dente L, Vetriani C, Zucconi A, Pelicci G, Lanfrancone L, Pelicci PG, Cesareni G.

J Mol Biol. 1997 Jun 27;269(5):694-703.

PMID:
9223634
40.

The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor.

Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, Pelicci PG, Ciardiello F.

Oncogene. 1997 Feb 27;14(8):923-8.

41.

Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway.

Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG.

EMBO J. 1997 Feb 17;16(4):706-16.

42.

Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation.

Brizzi MF, Dentelli P, Lanfrancone L, Rosso A, Pelicci PG, Pegoraro L.

Oncogene. 1996 Nov 21;13(10):2067-76.

PMID:
8950973
43.

Epidermal growth factor modulates pepsinogen secretion in guinea pig gastric chief cells.

Fiorucci S, Lanfrancone L, Santucci L, Calabro A, Orsini B, Federici B, Morelli A.

Gastroenterology. 1996 Oct;111(4):945-58.

PMID:
8831589
44.

The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation.

Milia E, Di Somma MM, Baldoni F, Chiari R, Lanfrancone L, Pelicci PG, Telford JL, Baldari CT.

Oncogene. 1996 Aug 15;13(4):767-75.

PMID:
8761298
45.

Not all Shc's roads lead to Ras.

Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci PG.

Trends Biochem Sci. 1996 Jul;21(7):257-61. Review.

PMID:
8755247
46.

Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation.

Lotti LV, Lanfrancone L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE, Falini B, Pelicci PG, Torrisi MR.

Mol Cell Biol. 1996 May;16(5):1946-54.

47.

Human lung carcinoma cells engineered to release IL2, IL7, GM-CSF and TNF alpha.

Guarini A, Riera L, Reato G, Carbone A, Cignetti A, Tos A, Lanfrancone L, Melani C, Paul R, Forni G, Foa R.

Int J Oncol. 1996 Apr;8(4):765-72.

PMID:
21544424
48.

An X chromosome-linked gene encoding a protein with characteristics of a rhoGAP predominantly expressed in hematopoietic cells.

Tribioli C, Droetto S, Bione S, Cesareni G, Torrisi MR, Lotti LV, Lanfrancone L, Toniolo D, Pelicci P.

Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):695-9.

49.

Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase.

Ricci A, Lanfrancone L, Chiari R, Belardo G, Pertica C, Natali PG, Pelicci PG, Segatto O.

Oncogene. 1995 Oct 19;11(8):1519-29.

PMID:
7478576
50.

Constitutive phosphorylation of Shc proteins in human tumors.

Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore PP, Pelicci PG.

Oncogene. 1995 Sep 7;11(5):899-907.

PMID:
7675449

Supplemental Content

Loading ...
Support Center